[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=8cf5edb3264552278345b67a617aadecd165b8648e3192480bedc4d16818e521",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756831200,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 136621001,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=8cf5edb3264552278345b67a617aadecd165b8648e3192480bedc4d16818e521"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Slid on Softer Revenue and Earnings",
    "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge All Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, growth stocks led the stock market to rebound from tariff uncertainty. The benchmark Russell 3000 Growth Index performed better as risk-on sentiment took hold, rising […]",
    "url": "https://finnhub.io/api/news?id=64701fceb680a71383b3d3136282024cbd436f7bc24758608418d5386aa0b872",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756819528,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Slid on Softer Revenue and Earnings",
      "id": 136610717,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge All Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, growth stocks led the stock market to rebound from tariff uncertainty. The benchmark Russell 3000 Growth Index performed better as risk-on sentiment took hold, rising […]",
      "url": "https://finnhub.io/api/news?id=64701fceb680a71383b3d3136282024cbd436f7bc24758608418d5386aa0b872"
    }
  },
  {
    "ts": null,
    "headline": "Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases",
    "summary": "LA JOLLA, Calif., September 02, 2025--Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals",
    "url": "https://finnhub.io/api/news?id=f0e172e01fc31d888ca4e51504b9a70ff79335eae649c5ad4a0782f32c0932b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756818000,
      "headline": "Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases",
      "id": 136610719,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "LA JOLLA, Calif., September 02, 2025--Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals",
      "url": "https://finnhub.io/api/news?id=f0e172e01fc31d888ca4e51504b9a70ff79335eae649c5ad4a0782f32c0932b8"
    }
  },
  {
    "ts": null,
    "headline": "Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy",
    "summary": "Satellos has the potential to produce substantial rewards if SAT-3247 can demonstrate sufficient muscle regeneration in DMD patients in a safe and tolerable manner",
    "url": "https://finnhub.io/api/news?id=e4f5b2a1cec25e853d2a35eacee8545aba742e26c824cb7353951412d2927c37",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756805845,
      "headline": "Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy",
      "id": 136606064,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166176/image_168166176.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Satellos has the potential to produce substantial rewards if SAT-3247 can demonstrate sufficient muscle regeneration in DMD patients in a safe and tolerable manner",
      "url": "https://finnhub.io/api/news?id=e4f5b2a1cec25e853d2a35eacee8545aba742e26c824cb7353951412d2927c37"
    }
  }
]